Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies and tends to be relatively resistant to conventional therapies. Activated Ras oncogene mutations are found in up to 90% of PDAC, leading to activation of the Ras/Raf/MEK/ERK signaling pathway. Sorafe...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Awasthi, Niranjan, Zhang, Changhua, Hinz, Stefan, Schwarz, Margaret A, Schwarz, Roderich E
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2013
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3618297/
https://ncbi.nlm.nih.gov/pubmed/23497499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-32-12
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky